Ångstrom Pharmaceuticals, Inc., a privately held pharmaceutical company headquartered in San Diego, California, is developing a new class of proprietary drugs that treat diseases involving cell migration, invasion, and metastasis. Ångstrom’s lead product, Å6 peptide, is a First-in-Class “Oncoparalytic”, stopping tumors from metastasizing by paralyzing cancer cells.